TreatmentTrends: Dry/Wet Age-Related Macular Degeneration (US) is an annual syndicated report series that offers a snapshot of dry and wet age-related macular degeneration (AMD) market dynamics and competitive landscape through comprehensive primary research with U.S. retinal specialists and general ophthalmologists. The report covers the current use of intravitreal injections, in particular anti-VEGF agents, for the treatment of AMD, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth, promotional activity, and anticipated use. In addition, respondents are queried about their awareness of and inter-est in products in development.

Questions Answered in This Report:

  • What is the relative AMD patient load by disease type (dry versus wet) and disease characteristics?

  • How are AMD patients currently being managed or treated and how does the approach differ by patient type? What differences in prescribing behavior exist based upon patient type (e.g., disease type, line of therapy, etc.)?

  • What product attributes are most important to physicians when they are se-lecting a specific wet AMD therapy? How do physicians perceive the cur-rently marketed intravitreal agents to perform against each attribute and against each other?

  • How is the use of each treatment approach and the prescribing of each AMD therapy anticipated to change over the next six months? What factors are driving the anticipated trends?

  • What sales strategies and messaging efforts are the marketers of the key AMD brands employing?

  • What is the current awareness of and interest in products in clinical develop-ment for dry or wet AMD among physicians?


Sample Frame & Methodology:

~100 fellowship-trained retinal specialists/general ophthalmologists com-plete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback.

To qualify, respondents must meet the following criteria:

Board-certified ophthalmologist

Minimum of 50 patients with wet AMD under management

Personally administer intravitreal injections to their wet AMD patients

Have been in practice a minimum of 2 years and a maximum of 35 years

More than 75% of professional time spent in clinical practice

Physician Research:

Retinal specialists and general ophthalmologists

Key Drugs Covered:

Avastin, Eylea, Lucentis, Macugen, Visudyne, emixustat hydrochloride (ACU-4429), lampalizumab, abicipar pegol (anti-VEGF DARPin), Fovista (E10030), iSONEP, Squalamine

Key Companies Mentioned:

Acucela, Allergan, Genentech, Lpath, Ohr Pharmaceuticals, Ophthotech, Otsuka, Regeneron, Roche, Valeant


- Final report in Powerpoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions

Related Reports:

- ChartTrends®: Wet AMD (U.S.) 2013

- TreatmentTrends®: Dry/Wet AMD (EU) 2014

- TreatmentTrends®: DR/DME (U.S.) 2014

- DecisionBase®: Wet AMD 2014

- DecisionBase®: Dry AMD 2014

- Physician and Payer Forum®: Wet AMD (U.S.) 2014

- Physician and Payer Forum®: Wet AMD (EU) 2014

- Pharmacor®: AMD 2014

- PatientBase®: Dry/Wet AMD 2014

- PatientBase®: Diabetic Retinopathy 2014

- PatientBase®: Diabetic Macular Edema 2014

- PatientBase®: Retinal Vein Occlusion 2014

Related Reports

Dry And Wet Age-Related Macular Degeneration - Landscape & Forecast - Disease Landscape & Forecast

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three

View Details

Age-Related Macular Degeneration | Disease Landscape and Forecast | G7 | 2020

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Reg...

View Details

Dry And Wet Age-Related Macular Degeneration - Special Topics - Dry And Wet Age-Related Macular Degeneration | Special Topics | Beovu: Nine Months Postlaunch For Wet AMD | US | 2020

Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of...

View Details